tiprankstipranks
Trending News
More News >
SynAct Pharma AB (DE:8F8)
:8F8
Advertisement

SynAct Pharma AB (8F8) Price & Analysis

Compare
0 Followers

8F8 Stock Chart & Stats


SynAct Pharma AB News

8F8 FAQ

What was SynAct Pharma AB’s price range in the past 12 months?
SynAct Pharma AB lowest stock price was €0.61 and its highest was €2.02 in the past 12 months.
    What is SynAct Pharma AB’s market cap?
    SynAct Pharma AB’s market cap is €98.20M.
      When is SynAct Pharma AB’s upcoming earnings report date?
      SynAct Pharma AB’s upcoming earnings report date is Aug 20, 2025 which is in 21 days.
        How were SynAct Pharma AB’s earnings last quarter?
        SynAct Pharma AB released its earnings results on May 27, 2025. The company reported -€0.045 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.045.
          Is SynAct Pharma AB overvalued?
          According to Wall Street analysts SynAct Pharma AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does SynAct Pharma AB pay dividends?
            SynAct Pharma AB does not currently pay dividends.
            What is SynAct Pharma AB’s EPS estimate?
            SynAct Pharma AB’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does SynAct Pharma AB have?
            SynAct Pharma AB has 49,874,542 shares outstanding.
              What happened to SynAct Pharma AB’s price movement after its last earnings report?
              SynAct Pharma AB reported an EPS of -€0.045 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -16.959%.
                Which hedge fund is a major shareholder of SynAct Pharma AB?
                Currently, no hedge funds are holding shares in DE:8F8

                Company Description

                SynAct Pharma AB

                SynAct Pharma AB, through its subsidiary, SynAct Pharma ApS, develops medicines for acute deterioration in inflammatory diseases. The company is developing AP1189, a drug candidate for the treatment of rheumatoid arthritis and idiopathic membranous glomerulonephritis. It has a partnership with the University Of Örebro to study the reduction of inflammation in vascular disease. The company was founded in 2012 and is headquartered in Lund, Sweden.

                SynAct Pharma AB (8F8) Earnings & Revenues

                Similar Stocks
                Company
                Price & Change
                Follow
                Oncopeptides AB
                Saniona AB
                IRLAB Therapeutics AB Class A
                Xspray Pharma AB
                Cantargia AB

                Ownership Overview

                100.00%
                Insiders
                Mutual Funds
                ― Other Institutional Investors
                100.00% Public Companies and
                Individual Investors

                Options Prices

                Currently, No data available
                ---
                Popular Stocks
                What am I Missing?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis